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LETTERS TO THE EDITOR
An Intrinsic Antibiotic Mechanism in Wounds and
Tissue-Engineered Skin
To the Editor
Despite the loss of epidermal barrier function and subsequent
exposure to environmental microorganisms, super®cial epidermal
wounds in vertebrates usually heal without major complications,
suggesting the existence of a functional antimicrobial mechanism
during wound healing. This general observation provides the basis
for testing a hypothesis for the existence of a functional
antimicrobial mechanism, which is active at cutaneous surfaces.
By using standard immunohistochemical techniques, we have
investigated expression of human b defensin-2 (hBD-2) in normal
and lesional human skin. hBD-2 is a member of the defensin family
of antimicrobial peptides, and has microbicidal activity to Gram
negative bacteria and Candida albicans (SchroÈder and Harder,
1999). Moreover, hBD-2 has been shown to provide a link
between innate and adaptive immunity (Yang et al, 1999). hBD-2
was ®rst isolated from psoriatic scales (Harder et al, 1997), and is
strongly expressed by psoriatic keratinocytes at sites of epidermal
in¯ammation (Liu et al, 1998; Fig 1a). Although hBD-2 was not
detected in the intact adult human epidermis (Fig 1b) or in the
neonatal corni®ed foreskin epidermis (Fig 1c), it was also clearly
detectable in the mucosal epithelium of the neonatal foreskin
(Fig 1d), a ®nding that may well explain why mucosal surfaces
rarely develop clinically relevant infections, despite the absence of a
stratum corneum. Most notably, this study shows that hBD-2 is
induced in the regenerating epidermis of acute surgical wounds
(Fig 1e), suggesting that keratinocyte activation in response to loss
of epidermal barrier function involves induction of an intrinsic
antibiotic mechanism. Of special interest is the observation that
hBD-2 is expressed in the epidermis of Apligraf (Fig 1f), a tissue-
engineered human skin equivalent (HSE) produced from neonatal
human foreskin. This product consisting of living ®broblasts
anchored in a bovine type I collagen lattice and living keratinocytes
forming a strati®ed epidermis has been developed for the treatment
of wounds (Wilkins et al, 1994) and has bene®cial effects in patients
with chronic venous leg ulcers (Falanga et al, 1998).
Unlike the other defensin genes, the hBD-2 gene contains
several binding sites for the nuclear transcription factor NF-kB (Liu
et al, 1998), which mediates responses to lipopolysaccharide (LPS)
and proin¯ammatory cytokines. Therefore, we determined if hBD-
2 expression is upregulated in the HSE following a topical bacterial
challenge or exposure to LPS. Topical treatment with 0.5 mg per ml
(5 ng per cm2) and 1 mg per ml (10 ng per cm2) puri®ed bacterial
LPS (from E. coli serotype 0127:B8; Sigma-Aldrich, Bucks,
Switzerland) for 24 h caused a strong, concentration-dependent,
and statistically signi®cant (p < 0.05) upregulation of hBD-2
expression (30.9 6 14.6 and 59.1 6 4.5; data represent fold change
versus untreated HSE 6 SEM). Recent studies have suggested that a
close interaction between CD14 and TLR4 participates in LPS
signaling, leading to nuclear translocation of NF-kB (Jiang et al
2000); however, to our knowledge, neither CD14 nor TLR-4 has
been found to be expressed in keratinocytes. Therefore, a CD14/
TLR-4 independent LPS response mechanism may exist in
keratinocytes. Alternatively, the possibility that a contaminant in
the used LPS preparation might be responsible for the strong
induction of hBD-2 in Apligraf cannot be excluded. Nevertheless,
the hBD-2 induction in keratinocytes appears to be the result of
pro-in¯ammatory processes, since other known chemical mediators
of skin in¯ammation, e.g., phorbol 12-myristate 13-acetate and
sodium lauryl sulfate, also enhanced hBD-2 mRNA expression in
the HSE (data not shown). To investigate the effect of bacterial
challenge on hBD-2 mRNA expression in Apliraf E. coli K12
bacteria grown over night in TY medium, pelleted, washed twice,
and resuspended in DMEM/HAM-F12 (1:1) cell culture medium,
were applied topically onto the epidermal surface of the HSE
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Figure 1. Immunostaining of hBD-2 in paraf®n sections of human
skin samples. Tissue samples were ®xed overnight in 4% paraformalde-
hyde/phosphate-buffered saline (PBS) pH 7.4 and then embedded in
paraf®n according to the standard procedures. Five micrometer sections
were dewaxed, rinsed in PBS pH 7.4 and incubated for 1 h in blocking
solution (PBS containing 1% bovine serum albumin and 0.1% tween 20)
prior to incubation with rabbit anti-hBD-2 polyclonal IgG (kindly
provided by Professor Thomas Ganz; Department of Medicine and
Pathology, UCLA School of Medicine, Los Angeles, CA; diluted 1:500 in
blocking solution) for 1 h at room temperature. Sections were subsequently
reacted with biotinylated goat antirabbit polyclonal antiserum (BioGenex,
San Ramon, CA) and streptavidine-alkaline phosphate complex
(BioGenex), each 30 min at room temperature. Staining was performed
with Fast Red chromogen (Sigma; F-4648) according to the instructions of
the supplier. Sections were counterstained with Mayer's Haematoxylin. (a)
Psoriatic lesion; (b) normal adult human skin; (c) corni®ed neonatal human
foreskin; (d) neonatal human foreskin mucosa; (e) edge of a normally
healing noninfected wound 3 d following injury; and (f) Apligraf.
Immunostaining is indicated by a deposition of red color.
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(approximately 106 bacteria per cm2). Bacterial challenge resulted in
a weak but signi®cant (p < 0.05) upregulation of hBD-2 mRNA
expression (2.0 6 0.4 after 24 h; 3.0 6 0.7 after 48 h; data represent
fold change versus untreated HSE 6 SEM) as revealed by standard
Real Time RT-PCR analysis. The observation that nonvirulent
bacteria are much weaker inducers of hBD-2 than virulent bacteria,
such as mucoid Pseudomonas aeruginosa (Harder et al, 2000), may
provide a rationale for the fact that only a weak induction of hBD-2
was achieved, although a rather high cell number of E. coli K12
bacteria was applied topically.
To investigate if hBD-2 expression in the epidermis has
functional relevance, we have soaked Apligraf with E. coli growth
medium and subsequently exposed its surface to E. coli followed by
a 24 h incubation at 37°C. Bacterial colonies did not grow on the
epidermal surface of the intact HSE, although colonies clearly
formed on the dermal surface exposed to bacteria following
mechanical separation of the epidermal layer.
In conclusion, the ®ndings of this study suggest that wound
healing involves induction of an intrinsic antibiotic mechanism,
which is also functional in epidermis of tissue-engineered skin.
The authors thank Prof. Tomas Ganz, UCLA School of Medicine, Los Angeles,
for kindly providing the anti-hBD2 antibody.
Peter Schmid, Olivier Grenet,* JesuÂs Medina,*
Salah-Dine Chibout,* Colin Osborne, David A. Cox
Dermatology Research and *Preclinical Safety,
Novartis Pharma Ltd, Basel, Switzerland
REFERENCES
Falanga V, Margolis D, Alvarez O, et al: Rapid healing of venous ulcers and lack of
clinical rejection with an allogeneic cultured human skin equivalent. Arch
Dermatol 134:293±300, 1998
Harder J, Bartels J, Christophers E, Schroeder M: A peptide antibiotic from human
skin. Nature 387:861, 1997
Harder J, Meyer-Hoffert U, Teran LM, Schwichtenberg L, Bartels J, Maune S,
SchroÈder JM: Mucoid Pseudomonas aeruginosa, TNF-alpha, and IL-1beta, but
not IL-6, induce human beta-defensin-2 in respiratory epithelia. Am J Respir
Cell Biol 22:714±721, 2000
Jiang Q, Akashi Ss, Miyake K, Petty HR: Lipopolysaccharide induces physivcal
proximity between CD14 and toll-like receptor 4 (TLR4) prior to nuclear
translocation of NF-kappaB. J Immunol 165:3541±3544, 2000
Liu L, Wang L, Jia HP, et al: Structure and mapping of the human beta-defensin
HBD-2 gene and its expression at sites of in¯ammation. Gene 222:237±244,
1998
SchroÈder J-M, Harder J: Molecules in focus: Human beta-defensin-2. Int J Biochem
Cell Biol 31:645±651, 1999
Wilkins LM, Watson SR, Prosky SJ, Meunier SF, Parenteau NL: Development of a
bilayered living skin construct for clinical application. Biotechnology
Bioengineering 43:747±756, 1994
Yang D, Chertov O, Bykovskaia SN, et al: b-defensins: Linking innate and adaptive
immunity through dendritic and T cell CCR6. Science 286:525±528, 1999
Coincident PTCH and BRCA1 Germline Mutations in a
Patient with Nevoid Basal Cell Carcinoma Syndrome and
Familial Breast Cancer
To the Editor
Nevoid basal cell carcinoma syndrome (NBCCS, OMIM no.
109400) is an autosomal dominant disease that is associated with
various developmental anomalies and different types of neoplasms
(Gorlin, 1987). Major manifestations are multiple basal cell
carcinomas (BCC), odontogenic keratocysts, palmar and plantar
dyskeratotic pits, and intracranial calci®cation (Evans et al, 1993;
Shanley et al, 1994). In addition, rib and vertebral malformations,
epidermal cysts, macrocephaly, facial anomalies, ovarian ®bromas,
and cerebellar medulloblastoma are associated with this syndrome.
NBCCS results from germline mutations in the human homolog of
the Drosophila segment polarity gene patched (PTCH) (Hahn et al,
1996; Johnson et al, 1996). PTCH maps to 9q22.3 and codes for a
transmembrane protein (Ptch) that functions as receptor for the
hedgehog family of signaling molecules (Wicking et al, 1999). So
far, more than 60 different PTCH germline mutations have been
found in NBCCS patients. There appears to be no genotype-
phenotype correlation (Wicking et al, 1997).
Here, we report on a 78-y-old woman who has undergone
multiple operations for BCC of the face and trunk since 1979. In
total, more than 300 BCC have been resected. She has also been
repeatedly operated on jaw keratocysts. At the age of 74 y, she
developed a carcinoma of the left breast that was treated by
mastectomy and lymphadenectomy. Histology showed multifocal
manifestation of invasive ductal carcinoma without regional lymph
node metastases or distant metastases [pT2m, pN0 (0/17), pM0,
G2]. Estrogen and progesteron receptors were negative. At present,
the patient is without recurrent breast carcinoma but still suffers
from multiple BCC of the face, neck, and trunk. Her family history
is remarkable as it does not only show NBCCS in both of her
daughters but also reveals a marked clustering of breast carcinomas
and other malignancies (Fig 1).
Breast carcinomas are not typically associated with NBCCS
(Evans et al, 1993; Shanley et al, 1994). We therefore decided to
investigate our patient for PTCH mutation as well as for mutation
of the hereditary breast and ovarian cancer gene BRCA1 (Miki et al,
1994). The patient gave her informed consent to both analyses. All
22 coding exons of PTCH were examined by single strand
con®rmation polymorphism analysis followed by direct sequencing.
A heterozygous transition mutation (c. 3394T>C, nucleotide
numbering according to GenBank accession no. U59464) was
found in the patient's constitutional DNA (Fig 2a). This mutation
translates into an exchange of serine to proline at codon 1132
(S1132P). The identical mutation was detected in one of the
patient's BCC (Fig 2a). We additionally investigated this BCC for
loss of heterozygosity (LOH) at three microsatellite markers from
9q22.3 (D9S287, D9S197, D9S280). LOH analysis was carried out
on DNA puri®ed from microdissected tumor areas. While D9S197
and D9S280 were constitutively homozygous, D9S287 demon-
strated LOH in the BCC (Fig 2b).
Mutational analysis of the entire BRCA1 coding region was
performed by denaturing high pressure liquid chromotography and
DNA sequencing (Arnold et al, 1999). The patient carried a
heterozygous germline mutation within exon 11, i.e., an insertion
of 31 bp at nucleotide 848 (c. 848ins817±847, nucleotide
numbering according to GenBank accession no. U14680) (Fig 2c).
This mutation results in a frameshift and introduces a premature
stop codon at position 247. The same mutation was found in the
patient's daughter (data not shown).
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